An explanatory video on NeurologyLive features Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, discussing the clinical use of Cognivue Clarity® and the new Cognivue Amyloid Risk Measure (CARM)*, and how these tools can inform clinical decisions and guide appropriate next steps in patient staging.
A NeurologyLive news article highlights findings from the Bio-Hermes study that led to the development of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).* In the piece, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, shares clinical insights on how CARM, together with the overall Cognivue Clarity® score, provides meaningful support in predicting amyloid positivity.
News article published on Conexiant about Cognivue’s value-add component now integrated into the Cognivue Clarity tool—The Cognivue Amyloid Risk Measure (CARM)*—a cognitive performance–based score that stratifies older adults by predicting likelihood of risk of cerebral amyloid deposition.
News article and an explanatory video published on NeurologyLive. In it, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, gives an informative explanation of the clinical application of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).*
Novel Cognivue CARM Score Feature Now Available on Cognivue Clarity Device; Marks Milestone in Alzheimer’s Early Detection Research
May 14, 2025
Neuroscience technology innovator Cognivue®, today announced a scientific breakthrough with the launch of the Cognivue Amyloid Risk Measure (CARM)*, a novel metric that predicts the likelihood of the presence of amyloid—a key biomarker of Alzheimer’s disease (AD). Now…
Cognivue Clarity®, a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence, will be evaluated in the Bio-Hermes-002 study.
October 30, 2024
Cognivue, Inc. announces strategic partnership with the Global Alzheimer’s Platform (GAP) as we participate in the Bio-Hermes-002 clinical trial study. As a GAP study partner, Cognivue will join Biogen and other participating…
Neuroscience technology innovator Cognivue, Inc. announced today that Paul W. Estes has been promoted to president, ushering in the company’s next stage of market evolution. He will guide the executive leadership team and oversee the company’s technology roadmap planning, new product expansion, partnership relations, sales, and staffing….
Neuroscience technology company Cognivue, Inc. has hired Ernest Fung, PsyD, ABPP, as vice president of Clinical and Medical Affairs. A distinguished clinical and forensic neuropsychologist, he brings a wealth of experience to Cognivue’s executive leadership team.
Cognivue President and CEO Tom O’Neill said, “Dr. Fung’s rare blend of business and clinical experience, combined with his specialization in cognitive performance assessment and knowledge of neurodegenerative disorders as well as traumatic brain injury, will further advance Cognivue’s innovative work. We are privileged to welcome him to our veteran team…
ROCHESTER, N.Y. (Aug. 2, 2023)—Cognivue, Inc. and DigiCARE Realized today announced a strategic partnership to improve routine brain care across health care systems, focusing on earlier detection of Alzheimer’s disease and related dementias (ADRD).
Coming on the heels of the landmark FDA approval of Leqembi, this collaboration will draw upon two transformative cognitive assessment technologies. DigiCARE Realized’s artificial…
A first-of-its-kind large-scale study conducted by the Kutcher Clinic for Sports Neurology aims to evaluate and refine how concussions are identified and treated using evidence-based diagnostic inputs. The study is funded in part by…
